Analgesic Efficacy and Safety of ADL5859 in Subjects With Acute Dental Pain After Third Molar Extraction
This study has been completed.
Sponsor:
Cubist Pharmaceuticals
Information provided by:
Cubist Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00993863
First received: October 9, 2009
Last updated: October 13, 2009
Last verified: October 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The objective of this study is to evaluate the analgesic efficacy and safety of ADL5859 compared with placebo and an active control (ibuprofen) in subjects with acute dental pain after third molar extraction.
| Condition | Intervention | Phase |
|---|---|---|
|
Acute Pain |
Drug: Placebo Drug: ADL5859 30 mg Drug: ADL5859 100 mg Drug: ADL5859 200 mg Drug: ibuprofen 400 mg |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Randomized, Single-Dose, Double-Blind, Active- and Placebo-Controlled Study of ADL5859 for the Treatment of Pain After Surgical Removal of Impacted Third Molars |
Resource links provided by NLM:
Further study details as provided by Cubist Pharmaceuticals:
Primary Outcome Measures:
- Total pain relief 0-4 hours after study medication [ Time Frame: 4 hours after study medication ] [ Designated as safety issue: No ]
| Enrollment: | 201 |
| Study Start Date: | June 2007 |
| Primary Completion Date: | September 2007 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Placebo Comparator: Placebo |
Drug: Placebo
single dose
|
| Experimental: ADL5859 30 mg |
Drug: ADL5859 30 mg
single dose
|
| Experimental: ADL5859 100 mg |
Drug: ADL5859 100 mg
single dose
|
| Experimental: ADL5859 200 mg |
Drug: ADL5859 200 mg
single dose
|
| Active Comparator: ibuprofen 400 mg |
Drug: ibuprofen 400 mg
single dose
Other Name: Advil
|
Eligibility| Ages Eligible for Study: | 18 Years to 50 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Key Inclusion Criteria:
- have 2 or more 3rd molars requiring extraction, including at least 1 partially or completely bone-impacted mandibular molar
- experience moderate to severe pain intensity as measured by the Numeric Pain Rating Scale (NPRS) (score ≥ 5) within 6 hours after surgery
- for male subjects, be surgically sterile or agree to use an appropriate method of contraception or have a sexual partner who is surgically sterile or using an insertable, injectable, transdermal, or combination oral contraceptive
- for female subjects, be using contraceptives, be postmenopausal, or have undergone hysterectomy or tubal ligation
- be able to take oral study medications
Key Exclusion Criteria:
- have positive results either on the urine screening tests for opiates, tetrahydrocannabinol,cocaine, amphetamines, barbiturates, benzodiazepines, phencyclidine, or propoxyphene or on the alcohol breathalyzer test
- have a history of alcoholism or drug addiction or abuse within 5 years before dosing with study medication
- have a history of chronic use (defined as daily use for > 2 weeks) of glucocorticoids,nonsteroidal anti-inflammatory drugs, or opiates for any condition within 6 months of study medication administration
- have a known allergy or history of significant reaction to any of the known treatment medications (ADL5859-like compounds or ibuprofen) or rescue pain medication (acetaminophen)
- have significant renal or hepatic disease, as indicated by clinical laboratory assessment
- have a known history of epilepsy or seizure disorder, including history of febrile seizure, or any other medical or psychiatric condition that, in the judgment of the investigator, would put the subject at risk while in the study, could influence the results of the study, or could negatively affect the subject's ability to participate in the study
- have a history or evidence of orthostatic hypotension at screening have a history of significant head trauma (head injury with loss of consciousness)
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Senior Medical Director, Clinical Research, Adolor Corporation |
| ClinicalTrials.gov Identifier: | NCT00993863 History of Changes |
| Other Study ID Numbers: | 33CL230, 33CL230 |
| Study First Received: | October 9, 2009 |
| Last Updated: | October 13, 2009 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Cubist Pharmaceuticals:
|
delta opioid agonist dental pain |
Additional relevant MeSH terms:
|
Ibuprofen Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions |
Anti-Inflammatory Agents Therapeutic Uses Antirheumatic Agents Cyclooxygenase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Central Nervous System Agents |
ClinicalTrials.gov processed this record on May 16, 2013